The genus Chlamydia is divided into three species: C. trachomatis, C. pneumoniae, and C. psittaci (15, 20) . C. trachomatis is primarily a pathogen of humans and has been divided into 15 serovars. C. pneumoniae, also a pathogen of humans, has one known serovar. C. psittaci encompasses a diverse group of strains that have a broad host range and pathogenic potential; it has been isolated from most species of birds and animals. These strains have been grouped by a number of methods (5, 8, 9, 31, 33, 34, 36) . Most of these studies have involved a narrow range of strains and have had limited success. The more extensive studies involving larger numbers of strains have used biotyping (36) , conventional sera (8, 9, 31) , monoclonal antibodies (MAbs) (1, 2, 14, 39, 41) , and genetic diversity (12, 13, 40) . The MAb studies in laboratories other than our own have used primarily groupreactive MAbs (14, 39, 41) . These studies have demonstrated that extensive diversity exists within the group and that a number of serologically distinct strains exist. Using serovarspecific MAbs, I have identified four serovars within the avian strains (2) .
The development of a rapid and precise method of serotyping C. psittaci isolates would benefit C. psittaci research. It would provide a tool for epidemiological studies to determine the distribution of a given serovar in both a geographic area and a host range. It would provide needed information about whether a given serovar is limited to specific clinical syndromes and/or to specific anatomical sites in the host. Serotyping will help answer questions about latency of infection and about the immune process by determining whether an infection is a recurrent infection or an exposure to a new serovar. Most important, serotyping will make it easier to compare results from different laboratories.
For a serotyping system to be successful for C. psittaci, it must be easy to perform, be reproducible, require a minimum of sample and materials, and be expandable to include new serovars. The use of the indirect microimmunofluorescence (IMIF) test with serovar-specific MAbs meets these requirements and has proven to be usable with C. trachomatis isolates (22, 43) . Earlier, I and others reported on the production of serovar-specific MAbs to C. psittaci and demonstrated that they could be used for serotyping isolates in the indirect fluorescent antibody technique (1-3). These MAbs have proven to be highly specific with little crossreactivity. The goal of this research was to develop a panel of MAbs that could be used with the IMIF test to rapidly serotype new C. psittaci isolates.
MATERIALS AND METHODS
Chlamydiae. The C. psittaci strains used and their origins are given in Table 1 group-reactive MAb to monitor the antigen preparation for adequate quantities of chlamydial elementary bodies. Each of the remaining six columns was used either as a negative control or for testing four dilutions of the appropriate MAbs. The chlamydial antigen used in the IMIF test was from either yolk sac or tissue culture harvest. The tissue culture harvest material was prepared from infected Vero cell monolayers. The tissue culture media, along with the disrupted tissue culture monolayer, were thoroughly mixed with a vortex mixer. The tissue culture harvest was mixed with a normal 20% yolk sac preparation at a ratio of 3:1. Yolk sac harvests of chlamydiae were used as a 10% yolk sac preparation. Samples were further diluted in phosphate-buffered saline (pH 7.2) if they contained too much yolk sac material for proper testing.
MAbs to 10 distinct serovars of C. psittaci were produced by the procedure reported earlier (3). The clones were selected for their ability to produce high levels of fluorescence with the homologous strain and no fluorescence with heterologous serovars.
One serovar-specific MAb to each of the known 10 serovars was selected for use in the panel of MAbs. The 10 MAbs were tested for serovar specificity by the IMIF test. They were screened at dilutions of 1:10, 1:20, 1:40, and 1:80 with the homologous strains and with representatives of the other known serovars. Positive clones were retested with a twofold dilution to determine an endpoint.
Serotyping. Fifty-five strains of C. psittaci were serotyped by the IMIF test as described above. Chlamydial antigen prepared as described above was dotted in the same pattern on two microscope slides. The first column of four wells was used for a group-reactive MAb. The remaining columns were used to test the sample with serovar-specific MAbs at dilutions of 1:100, 1:400, 1:1,600, and 1:6,400. A strain was considered to be a particular serotype if reactions were observed at 1:1,600 to 1:6,400 with one MAb and no reactions at 1:100 with the remaining serovar-specific MAbs. Isolates that reacted with the group-reactive MAb and not with any of the 10 serovar-specific MAbs were presumed to be members of a currently undefined serotype.
RESULTS
After MAbs from a number of fusions were tested for cross-reactions to different C. psittaci strains, a panel of 10 MAbs was selected to represent 10 serovars (Table 2 ). These MAbs were tested by the IMIF test for titers to each of 10 strains that were used to produce the MAbs ( Table 2 ). The results show that the MAbs are highly specific to the homologous strain, having titers of 1:1,280 or higher. Only two MAbs showed cross-reactions at 1:10. The MAb for the pigeon serovar (CP3/2A7) gave a weak reaction at 1:10 with the duck isolate (GD), and the MAb to the polyarthritis serovar (IPA/2G7) gave a reaction at 1:10 with the muskrat isolate (M56).
The 10 MAbs were used at dilutions of 1:100, 1:400, 1:1,600, and 1:6,400 to serotype 55 avian and mammalian strains ( Table 1) . Fifty of the strains reacted to only one serovar-specific MAb in the panel. These reactions were at the 1:1,600 or 1:6,400 dilution, easily serotyping the strain. Five strains failed to react with any of the serotype-specific MAbs, even though chlamydia was detected with the groupreactive MAb used as a control. These are presumed to be members of new serovars.
DISCUSSION
The use of serovar-specific MAbs in the IMIF test provides a rapid and highly specific method to serotype isolates of C. psittaci. Serotyping could be performed with small quantities of crude antigen grown in either tissue culture or eggs. The MAbs, when used at dilutions of 1:100, 1:400, 1:1,600, and 1:6,400, provided clear differentiation of the strains into different serovars. Each strain reacted with only one serovar-specific MAb at the 1:1,600 or higher dilution. No cross-reactions were observed even at the 1:100 dilution of the MAbs. The group-reactive MAb serves as a reliable control which demonstrates that adequate antigen is present for serotyping when isolates which fail to react with the serovar-specific MAbs are found. An isolate that fails to react can be assumed to be a member of an additional serovar; a serovar-specific MAb to it can readily be produced and added to the testing format. (5, 8, 9, 11-14, 31, 33, 34, 36, 44 (31, 36) . The results with feline pneumonitis and GPIC isolates are in agreement with those in earlier studies (13, 31, 36) . The divisions of the avian strains are more difficult to compare, as laboratories often use different strains. However, reports have shown differences in virulence among avian strains, and the highly virulent strains correspond with the turkey serovar in this study (44) . Others have also reported on differences between the psittacine and pigeon strains (5) . On the other hand, our current panel does not include some identified serovars, including serovars from swine, sheep, and cattle (31) .
The distribution of the hosts from which the strains were obtained clearly indicates that a relationship exists between the serovar of the strain and the species of the host. However, the natural relationship between serovars and hosts cannot be determined from our strains, as our collection includes strains submitted to us because of the unusual nature of the disease outbreak. The distribution of our strains among the serovars also is influenced by the perceived importance of chlamydiae in a given species, the ease of growing a given strain, and the emphasis in our laboratory over the past 25 years on avian species.
Five of the strains failed to react with any of the serovarspecific MAbs and are presumed to be members of additional serovars. These were from both avian and mammalian sources and are expected to represent two or more new serovars. We are currently seeking to determine the identities of these strains and will be producing MAbs to those representing new serovars. These MAbs will then be added to our panel of MAbs for serotyping.
